Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.34 |
| ▸ | FNTB | P49356 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15844698 | 1.00 | GPR84 (0.38) | GPR84FFAR1FFAR4CISD1KDM4E | |
| SCHEMBL14763319 | 1.00 | GPR84 (0.38) | GPR84FFAR1FFAR4CISD1KDM4E | |
| SCHEMBL14763577 | 1.00 | GPR84 (0.38) | GPR84FFAR1FFAR4CISD1KDM4E | |
| 1,5-Pentanediol SCHEMBL15844888 | 1.00 | GPR84 (0.38) | GPR84FFAR1FFAR4CISD1KDM4E | |
| SCHEMBL15845249 | 1.00 | GPR84 (0.38) | GPR84FFAR1FFAR4CISD1KDM4E | |
| Ethylene Glycol SCHEMBL11802063 | 0.91 | EGFR (0.37) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 | |
| SCHEMBL236959 | 0.87 | — | — | |
| SCHEMBL236960 | 0.87 | — | — | |
| Oxybate SCHEMBL29113123 | 0.86 | CAMK2A (0.52) | GPR84FFAR1FFAR4CISD1KDM4E | |
| Glycolic Acid SCHEMBL29113124 | 0.85 | EGFR (0.36) | CISD1KDM4ESLC16A3ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240271007-A1 | CYANOACRYLATE COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2024-08-15 | — | — | US | claimed |
| EP-2753442-B1 | DI-OR POLY-FUNCTIONAL ELECTRON DEFICIENT OLEFINS COATED METAL POWDERS FOR SOLDER PASTES | Henkel IP & Holding GmbH (DE) | 2019-10-30 | — | — | EP | claimed |
| US-20170233618-A1 | CYANOACRYLATE COMPOSITIONS | Henkel IP & Holding GmbH (DE) | 2017-08-17 | — | — | US | claimed |
| US-9657120-B1 | Cyanoacrylate compositions | Henkel IP & Holding GmbH (DE) | 2017-05-23 | — | — | US | claimed |
| US-9427829-B2 | Di- or poly-functional electron deficient olefins coated metal powders for solder paste | Henkel IP & Holding GmbH (DE) | 2016-08-30 | — | — | US | claimed |
| US-20140182746-A1 | DI- OR POLY-FUNCTIONAL ELECTRON DEFICIENT OLEFINS COATED METAL POWDERS FOR SOLDER PASTE | Henkel IP & Holding GmbH (DE) | 2014-07-03 | — | — | US | claimed |
| US-20250339580-A1 | MEDICAL TISSUE ADHESIVE COMPOSITION | OKAPI MEDICAL LLC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12357581-B2 | Nanoparticles comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits | SINTEFF TTO AS (NO) | 2025-07-15 | — | — | US | disclosed |
| EP-4570791-A1 | THIOESTER PHOTOINITIATORS | ARKEMA FRANCE (FR) | 2025-06-18 | — | — | EP | disclosed |
| EP-4571417-A1 | PROCESS OF CURING ETHYLENICALLY UNSATURATED COMPOUNDS WITH COUMARIN THIOESTER PHOTOINITIATORS | ARKEMA FRANCE (FR) | 2025-06-18 | — | — | EP | disclosed |
| EP-4570860-A1 | COUMARIN THIOESTER PHOTOINITIATORS | ARKEMA FRANCE (FR) | 2025-06-18 | — | — | EP | disclosed |
| US-20240240064-A1 | TWO-PART CURABLE COMPOSITION | BOSTIK SA (FR) | 2024-07-18 | — | — | US | disclosed |
| EP-4029675-B1 | 3D-PRINTING METHODS AND SYSTEMS | BOSTIK SA (FR) | 2024-05-29 | — | — | EP | disclosed |
| US-9657120-B1 | Cyanoacrylate compositions | Henkel IP & Holding GmbH (DE) | 2017-05-23 | — | — | US | disclosed |
| US-20170022151-A1 | PROCESS FOR PREPARING 1,1-DISUBSTITUTED ETHYLENE MONOMERS | AFINITICA TECHNOLOGIES, S. L. (ES) | 2017-01-26 | — | — | US | disclosed |
| US-9427829-B2 | Di- or poly-functional electron deficient olefins coated metal powders for solder paste | Henkel IP & Holding GmbH (DE) | 2016-08-30 | — | — | US | disclosed |
| CN-104977807-A | Photosensitive resin composition, color filter and manufacturing method thereof, and liquid crystal display device | CHI MEI CORP | 2015-10-14 | — | — | CN | disclosed |
| US-20150285973-A1 | PHOTOSENSITIVE RESIN COMPOSITION, COLOR FILTER AND METHOD FOR MANUFACTURING THE SAME, AND LIQUID CRYSTAL DISPLAY APPARATUS | CHI MEI CORPORATION (TW) | 2015-10-08 | — | — | US | disclosed |
| EP-2927209-A1 | Process for preparing 1,1-disubstituted ethylenic monomers | Afinitica Technologies, S. L. (ES) | 2015-10-07 | — | — | EP | disclosed |
| US-20140182746-A1 | DI- OR POLY-FUNCTIONAL ELECTRON DEFICIENT OLEFINS COATED METAL POWDERS FOR SOLDER PASTE | Henkel IP & Holding GmbH (DE) | 2014-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12357581-B2 | Nanoparticles comprising copolymeric or homopolymeric compounds which comprise cyanoacrylate subunits | CD47, PSMA2, C3AR1 | GPR84 2091/4885FFAR1 2800/4885FFAR4 3806/4885 |
| US-20170022151-A1 | PROCESS FOR PREPARING 1,1-DISUBSTITUTED ETHYLENE MONOMERS | ESD, AP1M1, SULT1A1 | GPR84 4143/4885FFAR1 2679/4885FFAR4 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.